Equity Overview
Price & Market Data
Price: $1.44
Daily Change: $0.00 / 0.00%
Range: $1.38 - $1.50
Market Cap: $120,668,560
Volume: 176,987
Performance Metrics
1 Week: 3.55%
1 Month: 31.53%
3 Months: 29.20%
6 Months: 0.69%
1 Year: -48.95%
YTD: 14.06%
Company Details
Employees: 22
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.